TED W LOVE
CIK 1188919 · President and CEO · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.06M
Companies
17
Total Filings
115
Lifetime Open-Market Net
-$14.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JAZZ | Director | 3,132 | $253.07 | $792.6K | $0 | 3 | 2026-08-07 |
| GPCR | Director | — | $53.53 | — | $0 | 4 | 2026-06-18 |
| RPRX | Director | 58,393 | $59.69 | $3.49M | $0 | 7 | 2026-06-08 |
| GILD | Director | 5,484 | $143.44 | $786.6K | $0 | 4 | 2026-05-04 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $0 | 5 | 2023-12-15 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | President and CEO | 0 | $68.49 | $0 | -$16.20M | 35 | 2022-10-06 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 3 | 2020-07-02 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 131,000 | $14.49 | $1.90M | $0 | 11 | 2020-06-08 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 37,394 | — | — | $97.5K | 5 | 2017-09-26 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 13,005 | — | — | $0 | 4 | 2015-09-28 |
| HUMANIGEN, INC (KBIO) Delisted | Director | — | — | — | $0 | 2 | 2015-07-14 |
| MSTX | Director | — | $7.81 | — | $0 | 1 | 2013-06-21 |
| SANTARUS INC (SNTS) Delisted | Director | 335,500 | — | — | $2.01M | 11 | 2013-06-12 |
| Savara Inc (ANX) Delisted | Director | — | — | — | $0 | 1 | 2012-09-07 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, R&D and Tech. Operations | 77,756 | — | — | -$387.7K | 6 | 2012-07-27 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | Director | — | $28.80 | — | $0 | 2 | 2010-02-09 |
Recent Filings · Page 11 of 12
115 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-06-11 | SANTARUS INC (SNTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-05-26 | AFFYMAX INC (AFFY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-02-09 | Oruka Therapeutics, Inc. (ABIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-02-03 | ONYX PHARMACEUTICALS INC (ONXX) Delisted | Grant (A) | +16,500 | $0 | EDGAR |
| 2009-06-12 | SANTARUS INC (SNTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-05-29 | AFFYMAX INC (AFFY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-03-17 | SANTARUS INC (SNTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-03-03 | Oruka Therapeutics, Inc. (ABIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-06-16 | SANTARUS INC (SNTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-23 | AFFYMAX INC (AFFY) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.